Filapixant
Based on 1 Customer Validation
Filapixant (BAY 1902607) is an orally active and selective P2X3 receptor antagonist. Filapixant is applicable to the research of refractory chronic cough.
Para uso exclusivo en investigación. No vendemos a pacientes.
- Pureza : 99.10%
- No. CAS: 1948232-63-0
- Fòrmula: C24H26F3N5O3S
- Peso molecular:521.56
-
Almacenamiento:Powder -20°C, 3 years ; In solvent -80°C, 6 months , -20°C, 1 month
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Actividad biológica
-
Chemical Information
-
Solvente y solubilidad
- Pureza y Documentación
- Referencias
-
Help & FAQs
-
HY-136026
CamlipixantP2X3 Antagonist -
HY-50697
A-740003P2X Receptor Antagonist -
HY-D0014
Brilliant blue G-250Dye/P2×7R Antagonist -
HY-101588
GefapixantP2X3 Antagonist -
HY-15488A
A 438079 hydrochlorideP2X7 Receptor Antagonist -
HY-101418
JNJ-47965567P2X7 Antagonist -
HY-101910
PSB-12062P2X4 antagonist -
HY-108669
AZ10606120 dihydrochlorideP2X Receptor Antagonist -
HY-D0976
NF279P2X1 Receptor Antagonist -
HY-108670
AZ 11645373P2X7 Receptor Antagonists -
HY-14483
AF-353P2X Receptor Antagonist -
HY-13954
A 839977P2X7 Antagonist
Ver todos los productos específicos de isoformas P2X Receptor
More
Actividad biológica
Descripciòn
IC50 & Target
[1]|
P2X3 Receptor |
CYP3A4 |
In Vitro
Chemical Information
-
No. CAS 1948232-63-0
-
Appearance Solid
-
Peso molecular 521.56
-
Fòrmula C24H26F3N5O3S
-
Color White to light yellow
-
SMILES
O=C(N[C@@H](C1=CN=C(C(F)(F)F)N=C1)C)C2=CC(C3=NC=C(C)S3)=CC(OC[C@H]4CN(C)CCO4)=C2
-
Synonyms
BAY 1902607
-
Envío
Room temperature in continental US; may vary elsewhere.
-
Almacenamiento
Powder -20°C 3 years In solvent -80°C 6 months -20°C 1 month
Solvente y solubilidad
In Vitro:
DMSO : 146.67 mg/mL (281.21 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
In Vivo:
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: 5.5 mg/mL (10.55 mM); Suspended solution; Need ultrasonic
This protocol yields a suspended solution of 5.5 mg/mL. Suspended solution can be used for oral and intraperitoneal injection.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (55.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: 5.5 mg/mL (10.55 mM); Suspended solution; Need ultrasonic
This protocol yields a suspended solution of 5.5 mg/mL. Suspended solution can be used for oral and intraperitoneal injection.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (55.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
In Vivo Dissolution Calculator
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Pureza y Documentación
-
Ficha de datos (273 KB)
-
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
-
Instrucciones de manejo (2659 KB)
Referencias
[1]. Francke K, et al. Investigation of the Relevance of CYP3A4 Inhibition on the Pharmacokinetics of the Novel P2X3 Antagonist Filapixant: Results of In Vitro Explorations and a Fixed-Sequence Clinical Trial with Itraconazole in Healthy Volunteers. Int J Mol Sci. 2025;26(20):10177. Published 2025 Oct 20. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 1.9173 mL | 9.5866 mL | 19.1732 mL | 47.9331 mL |
| 5 mM | 0.3835 mL | 1.9173 mL | 3.8346 mL | 9.5866 mL | |
| 10 mM | 0.1917 mL | 0.9587 mL | 1.9173 mL | 4.7933 mL | |
| 15 mM | 0.1278 mL | 0.6391 mL | 1.2782 mL | 3.1955 mL | |
| 20 mM | 0.0959 mL | 0.4793 mL | 0.9587 mL | 2.3967 mL | |
| 25 mM | 0.0767 mL | 0.3835 mL | 0.7669 mL | 1.9173 mL | |
| 30 mM | 0.0639 mL | 0.3196 mL | 0.6391 mL | 1.5978 mL | |
| 40 mM | 0.0479 mL | 0.2397 mL | 0.4793 mL | 1.1983 mL | |
| 50 mM | 0.0383 mL | 0.1917 mL | 0.3835 mL | 0.9587 mL | |
| 60 mM | 0.0320 mL | 0.1598 mL | 0.3196 mL | 0.7989 mL | |
| 80 mM | 0.0240 mL | 0.1198 mL | 0.2397 mL | 0.5992 mL | |
| 100 mM | 0.0192 mL | 0.0959 mL | 0.1917 mL | 0.4793 mL |
Filapixant Related Classifications
HY-109173 Related Classifications
Powered by Bioz